Bioanalysis special focus issue on antibody-drug conjugates

“As knowledge emerges from the breadth of antibody–drug conjugates currently in development within the industry, it will help to shape best practices for bioanalysis of antibody–drug conjugates.” Antibody–drug conjugates (ADCs) contain a cytotoxic drug covalently bound to a monoclonal antibody via a synthetic linker. The concept of an ADC is to deliver the highly potent cytotoxic agent specifically to tumors with minimal impact on normal tissues. This relies on designing the ADC to bind to target antigens that are overexpressed on the surface of the tumor, but minimally expressed on normal tissues.This is followed by internalization, trafficking to the lysosome...